Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

Roche has been shocked by the late-stage trial failure of its immunotherapy Tecentriq in bladder cancer, a setback which could cost it billions if the drug loses its licence.

Roche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC), giving the drug a lead in early-stage cases that can be ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Xilio is leveraging its proprietary platform to advance a pipeline of research-stage programs for tumor-activated bispecific ...

Roche announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December 2024 in San ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Zepzelca, used in combination with Roche’s Tecentriq, outperformed Tecentriq alone when used as a first-line maintenance treatment in ES-SCLC following induction therapy with Tecentriq and chemo ...

Shares of Jazz Pharmaceuticals JAZZ rose nearly 6% on Tuesday after it reported positive top-line results from the phase III IMforte study, which evaluated Zepzelca (lurbinectedin), combined with ...